View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 13, 2022

Juniper Biologics licenses Kolon’s gene therapy for knee osteoarthritis

Juniper will develop and market TG-C LD in the Asia Pacific, the Middle East and Africa under the $600m licensing deal.

Juniper Biologics has obtained the licensing rights for the development and commercialisation of Kolon Life Science’s cell-mediated gene therapy, TissueGene-C low dose (TG-C LD), to treat knee osteoarthritis.

A non-surgical investigational therapy, TG-C LD is claimed to be the first in the world to potentially treat knee osteoarthritis, which is a common form of arthritis.

It is administered as a single intra-articular injection. 

Under the $600m licencing deal, Juniper will develop and market the gene therapy to medical professionals and hospitals in the Asia Pacific, the Middle East and Africa.

Furthermore, Kolon will extend support for the gene therapy development and supply.

TG-C’s licence holder in the US, Kolon TissueGene, has concluded a Phase II clinical trial in the country.

Preliminary findings from the trial showed that a single injection of TG-C in the knee joint offered lasting pain relief and improvement in mobility for possibly up to two years.

Phase III trials enrolling 1,020 patients in the US are currently underway to validate the safety and efficacy of TG-C. 

Apart from establishing the statistically significant decline in pain and function improvements reported in the US Phase II trial, these trials are intended to demonstrate the delay of disease progression to obtain a Disease-Modifying Osteoarthritis Drug designation.

Juniper Biologics CEO Raman Singh said: “We are always looking to identify areas in which we can make the most difference and TG-C LD offers substantial relief for knee osteoarthritis patients who would otherwise be in need of surgery or other treatment options. 

“We are committed to providing innovative treatments to treat osteoarthritis of the knee through the regeneration of cartilage and we believe this innovative investigational treatment will bring relief to millions of patients across the region.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU